Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer

Details for Australian Patent Application No. 2009246263 (hide)

Owner Amgen Inc.

Inventors Coxon, Angela; Beaupre, Darrin; Polverino, Anthony J.; Dussault, Isabelle; Kaplan-Lefko, Paula; Burgess, Theresa L.

Agent Shelston IP

Pub. Number AU-A-2009246263

PCT Pub. Number WO2009/140549

Priority 61/127,753 14.05.08 US

Filing date 14 May 2009

Wipo publication date 19 November 2009

International Classifications

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 31/395 (2006.01) - having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins

A61K 31/404 (2006.01)

A61K 31/435 (2006.01) - having six-membered rings with one nitrogen as the only ring hetero atom

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

18 November 2010 PCT application entered the National Phase

  PCT publication WO2009/140549 Priority application(s): WO2009/140549

20 January 2011 Amendment Made

  The nature of the amendment is: Amend co-inventor name from Burgess, Theresa L. to Burgess, Teresa L.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009246264-Ethylene-tetrafluoroethylene intermediates

2009246256-Biomarkers for the identification, monitoring, and treatment of head and neck cancer